Bone marrow (BM) mesenchymal stromal cells (MSCs) provide microenvironmental support to hematopoietic stem and progenitor cells (HSPCs). Culture-expanded MSCs are interesting candidates for cellular therapies due to their immunosuppressive and regenerative potential which can be further enhanced by pretreatment with interferon-gamma (IFN-γ). However, it remains unknown whether IFN-γ can also influence hematopoietic support by BM-MSCs. In this study, we elucidate the impact of IFN-γ on the hematopoietic support of BM-MSCs. We found that IFN-γ increases expression of interleukin (IL)-6 and stem cell factor by human BM-MSCs. IFN-γ-treated BM-MSCs drive HSPCs toward myeloid commitment in vitro, but impair subsequent differentiation of HSPC. Moreover, IFN-γ-ARE-Del mice with increased IFN-γ production specifically lose their BM-MSCs, which correlates with a loss of hematopoietic stem cells' quiescence. Although IFN-γ treatment enhances the immunomodulatory function of MSCs in a clinical setting, we conclude that IFN-γ negatively affects maintenance of BM-MSCs and their hematopoietic support in vitro and in vivo.
Get full access to this article
View all access options for this article.
References
1.
MorrisonSJ and ScaddenDT. (2014). The bone marrow niche for haematopoietic stem cells. Nature, 505:327–334.
2.
DingL, SaundersTL, EnikolopovG and MorrisonSJ. (2012). Endothelial and perivascular cells maintain haematopoietic stem cells. Nature, 481:457–462.
3.
GreenbaumA, HsuYM, DayRB, SchuettpelzLG, ChristopherMJ, BorgerdingJN, NagasawaT and LinkDC. (2013). CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature, 495:227–230.
4.
Beyer NardiN and da Silva MeirellesL. (2006). Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol, 174:249–282.
5.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS and MarshakDR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
6.
MajumdarMK, ThiedeMA, HaynesworthSE, BruderSP and GersonSL. (2000). Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res, 9:841–848.
7.
HorwitzEM, ProckopDJ, FitzpatrickLA, KooWW, GordonPL, NeelM, SussmanM, OrchardP, MarxJC, PyeritzRE and BrennerMK. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med, 5:309–313.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
10.
Le BlancK, SamuelssonH, GustafssonB, RembergerM, SundbergB, ArvidsonJ, LjungmanP, LonniesH, NavaS and RingdenO. (2007). Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 21:1733–1738.
11.
SivanathanKN, GronthosS, Rojas-CanalesD, ThierryB and CoatesPT. (2014). Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev, 10:351–375.
12.
TobinLM, HealyME, EnglishK and MahonBP. (2013). Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol, 172:333–348.
13.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB and BartholomewA. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
14.
LiuY, WangL, KikuiriT, AkiyamaK, ChenC, XuX, YangR, ChenW, WangS and ShiS. (2011). Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med, 17:1594–1601.
15.
DuijvesteinM, WildenbergME, WellingMM, HenninkS, MolendijkI, van ZuylenVL, BosseT, VosAC, de Jonge-MullerES, et al. (2011). Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells, 29:1549–1558.
16.
CornelissenAS, MaijenburgMW, NolteMA and VoermansC. (2015). Organ-specific migration of mesenchymal stromal cells: who, when, where and why?. Immunol Lett, 168:159–169.
17.
MaijenburgMW, van der SchootCE and VoermansC. (2012). Mesenchymal stromal cell migration: possibilities to improve cellular therapy. Stem Cells Dev, 21:19–29.
18.
ChinnaduraiR, CoplandIB, GarciaMA, PetersenCT, LewisCN, WallerEK, KirkAD and GalipeauJ. (2016). Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNgamma licensing. Stem Cells, 34:2429–2442.
19.
EnglishK, MahonBP and WoodKJ. (2014). Mesenchymal stromal cells; role in tissue repair, drug discovery and immune modulation. Curr Drug Deliv, 11:561–571.
20.
YangL, DybedalI, BryderD, NilssonL, SitnickaE, SasakiY and JacobsenSE. (2005). IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol, 174:752–757.
21.
MatatallKA, ShenCC, ChallenGA and KingKY. (2014). Type II interferon promotes differentiation of myeloid-biased hematopoietic stem cells. Stem Cells, 32:3023–3030.
22.
de BruinAM, DemirelO, HooibrinkB, BrandtsCH and NolteMA. (2013). Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. Blood, 121:3578–3585.
23.
de BruinAM, VoermansC and NolteMA. (2014). Impact of interferon-gamma on hematopoiesis. Blood, 124:2479–2486.
24.
PaciejewskaMM, MaijenburgMW, GilissenC, KleijerM, VermeulK, WeijerK, VeltmanJA, von LindernM, van der SchootCE and VoermansC. (2016). Different balance of Wnt signaling in adult and fetal bone marrow-derived mesenchymal stromal cells. Stem Cells Dev, 25:934–947.
25.
KlamerSE, KuijkCG, HordijkPL, van der SchootCE, von LindernM, van HennikPB and VoermansC. (2013). BIGH3 modulates adhesion and migration of hematopoietic stem and progenitor cells. Cell Adh Migr, 7:434–449.
26.
HodgeDL, BerthetC, CoppolaV, KastenmullerW, BuschmanMD, SchaughencyPM, ShirotaH, ScarzelloAJ, SubleskiJJ, et al. (2014). IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. J Autoimmun, 53:33–45.
27.
MignoneJL, KukekovV, ChiangAS, SteindlerD and EnikolopovG. (2004). Neural stem and progenitor cells in nestin-GFP transgenic mice. J Comp Neurol, 469:311–324.
28.
Le BlancK, TammikC, RosendahlK, ZetterbergE and RingdenO. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 31:890–896.
29.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
30.
VidalC, BermeoS, LiW, HuangD, KremerR and DuqueG. (2012). Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized mice. Stem Cells, 30:1042–1048.
31.
DuqueG, HuangDC, MacorittoM, RivasD, YangXF, Ste-MarieLG and KremerR. (2009). Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis. Stem Cells, 27:550–558.
32.
Croitoru-LamouryJ, LamouryFM, CaristoM, SuzukiK, WalkerD, TakikawaO, TaylorR and BrewBJ. (2011). Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One, 6:e14698.
33.
IshiharaK and HiranoT. (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev, 13:357–368.
34.
SchurchCM, RietherC and OchsenbeinAF. (2014). Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells. Cell Stem Cell, 14:460–472.
35.
KerstJM, Slaper-CortenbachIC, van der SchootCE, HooibrinkB, von dem BorneAE and van OersRH. (1993). Interleukin-6 is a survival factor for committed myeloid progenitor cells. Exp Hematol, 21:1550–1557.
36.
JingD, FonsecaAV, AlakelN, FierroFA, MullerK, BornhauserM, EhningerG, CorbeilD and OrdemannR. (2010). Hematopoietic stem cells in co-culture with mesenchymal stromal cells—modeling the niche compartments in vitro. Haematologica, 95:542–550.
37.
OubariF, AmirizadeN, MohammadpourH, NakhlestaniM and ZarifMN. (2015). The important role of FLT3-L in ex vivo expansion of hematopoietic stem cells following co-culture with mesenchymal stem cells. Cell J, 17:201–210.
38.
PinhoS, LacombeJ, HanounM, MizoguchiT, BrunsI, KunisakiY and FrenettePS. (2013). PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med, 210:1351–1367.
39.
Mendez-FerrerS, MichurinaTV, FerraroF, MazloomAR, MacarthurBD, LiraSA, ScaddenDT, Ma'ayanA, EnikolopovGN and FrenettePS. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature, 466:829–834.
40.
OikonomopoulosA, van DeenWK, ManansalaAR, LaceyPN, TomakiliTA, ZimanA and HommesDW. (2015). Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep, 5:16570.
41.
TzengYS, LiH, KangYL, ChenWC, ChengWC and LaiDM. (2011). Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood, 117:429–439.
42.
KielMJ, YilmazOH, IwashitaT, YilmazOH, TerhorstC and MorrisonSJ. (2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell, 121:1109–1121.
43.
YangZX, MaoGX, ZhangJ, WenXL, JiaBB, BaoYZ, LvXL, WangYZ and WangGF. (2017). IFN-gamma induces senescence-like characteristics in mouse bone marrow mesenchymal stem cells. Adv Clin Exp Med, 26:201–206.
44.
ChinnaduraiR, RajanD, NgS, McCulloughK, ArafatD, WallerEK, AndersonLJ, GibsonG and GalipeauJ. (2017). Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNgamma priming. Blood Adv, 1:628–643.
45.
GuessAJ, DaneaultB, WangR, BradburyH, La PerleKMD, FitchJ, HedrickSL, HamelbergE, AstburyC, et al. (2017). Safety profile of good manufacturing practice manufactured interferon gamma-primed mesenchymal stem/stromal cells for clinical trials. Stem Cells Transl Med, 6:1868–1879.
46.
O'Hagan-WongK, NadeauS, Carrier-LeclercA, ApablazaF, HamdyR, Shum-TimD, RodierF and ColmegnaI. (2016). Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells' homeostasis. Oncotarget, 7:13285–13296.
47.
ZambettiNA, PingZ, ChenS, KenswilKJ, MylonaMA, SandersMA, HoogenboezemRM, BindelsEM, AdistyMN, et al. (2016). Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell, 19:613–627.
48.
AbbuehlJP, TatarovaZ, HeldW and HuelskenJ. (2017). Long-term engraftment of primary bone marrow stromal cells repairs niche damage and improves hematopoietic stem cell transplantation. Cell Stem Cell, 21:241–255 e6.
49.
LinFC, KarwanM, SalehB, HodgeDL, ChanT, BoelteKC, KellerJR and YoungHA. (2014). IFN-gamma causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood, 124:3699–3708.
50.
DingL and MorrisonSJ. (2013). Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature, 495:231–235.
51.
HamzicE, WhitingK, Gordon SmithE and PettengellR. (2015). Characterization of bone marrow mesenchymal stromal cells in aplastic anaemia. Br J Haematol, 169:804–813.
52.
ChaoYH, PengCT, HarnHJ, ChanCK and WuKH. (2010). Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol, 89:715–723.
53.
LiJ, YangS, LuS, ZhaoH, FengJ, LiW, MaF, RenQ, LiuB, et al. (2012). Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia. PLoS One, 7:e47764.
54.
ZoumbosNC, GasconP, DjeuJY and YoungNS. (1985). Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A, 82:188–192.
55.
MichelozziIM, PievaniA, PagniF, AntoliniL, VernaM, CortiP, RovelliA, RiminucciM, DazziF, BiondiA and SerafiniM. (2016). Human aplastic anaemia-derived mesenchymal stromal cells form functional haematopoietic stem cell niche in vivo. Br J Haematol, 179:669–673.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
